Funding for this research was provided by:
agency for healthcare research and quality (R18HS026874)
Received: 26 August 2021
Accepted: 20 January 2022
First Online: 2 February 2022
: Regulatory approval was obtained from the Ann Arbor VA and University of Michigan institutional review boards. Verbal informed consent was obtained from each interviewee.
: Dr. Barnes discloses consulting fees from Pfizer/Bristol Myers Squibb and Janssen. Dr. Dorsch is supported by R18 HS026874 and R21 HS026322 from the Agency for Health Research and Quality, R01 AG062582 from the National Institutes of Health (NIH)/National Institute of Aging, and the American Health Association Health IT Research Network; has received honoraria from Janssen; and has received research funding from Bristol Myers Squibb/Pfizer and Amgen in the past 2 years. The other authors have no disclosures.